Mineralys Therapeutics (MLYS) Current Assets (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Current Assets data on file, last reported at $652.5 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 84.05% year-over-year to $652.5 million; the trailing twelve-month figure through Mar 2026 stood at $652.5 million (up 84.05% YoY), and the FY2025 full-year result was $661.4 million, up 222.08% from the prior year.
• Current Assets eased to $652.5 million in Q1 2026, from $661.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $661.4 million in Q4 2025 to a low of $112.8 million in Q4 2022.
• A 5-year average of $351.0 million and a median of $296.6 million in 2023 frame the typical range for Current Assets.
• Across the five-year window, Current Assets decreased 17.56% in 2024 and jumped 222.08% in 2025, its largest moves.
• Tracing MLYS's Current Assets over 5 years: stood at $112.8 million in 2022, then surged by 120.81% to $249.1 million in 2023, then retreated by 17.56% to $205.4 million in 2024, then jumped by 222.08% to $661.4 million in 2025, then fell by 1.35% to $652.5 million in 2026.
• Business Quant data shows MLYS's Current Assets at $652.5 million in Q1 2026, $661.4 million in Q4 2025, and $599.8 million in Q3 2025.